Nature communications · 2026
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boruah Nabamita, Hoyos David, Moses Renyta, Hausler Ryan, Desai Heena, Le Anh N, Good Madeline, Kelly Gregory, Raghavakaimal Ashvathi, Tayeb Maliha, Narasimhamurthy Mohana, Doucette Abigail, Gabriel Peter, Feldman Michael J, Park Jinae, Lopez de Rodas Miguel, Schalper Kurt A, Goldfarb Shari B, Nayak Anupma, Levine Arnold J, Greenbaum Benjamin D, Maxwell Kara N
Аннотация
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer (BC) is the most common cancer in LFS females. Here, we perform a multimodal analysis, comparing LFS-BC with sporadic premenopausal breast cancer which shows that nearly all LFS-BC undergo biallelic loss of TP53, with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibit a high burden of short amplified aneuploid segments. Pro-apoptotic p53 target genes BAX and TP53I3 fail to be up-regulated in LFS-BC unlike in sporadic BC compared to normal breast tissue. LFS-BC has lower CD8 + T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC is marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.